S

Shin Nippon Biomedical Laboratories Ltd
F:YB3

Watchlist Manager
Shin Nippon Biomedical Laboratories Ltd
F:YB3
Watchlist
Price: 8.3 EUR -2.35%
Market Cap: €345.5m

Shin Nippon Biomedical Laboratories Ltd
Investor Relations

Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 986 full-time employees. The company went IPO on 2004-03-08. The firm has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.
President, Chairman, CEO, Group CFO, Fisheries Business Officer & Chief Health Officer
No Bio Available
Fumihiko Makino
Senior Executive Officer, Financial Controller and GM of Finance & Accounting
No Bio Available
Toshiyuki Iwata
Managing Executive Officer, R/PR Division Manager & Sustainability Officer
No Bio Available
Shinji Nitanda
Senior MD of Corporate Development & Corporate Tax Administration and Director
No Bio Available
Kyomi Nagatoshi
Senior Managing Executive Officer, Head of General Affairs & Human Resources and Director
No Bio Available
Mr. Ken Takanashi CPA, MBA.
Executive VP of Group Corporate Management & Global Business & Director
No Bio Available
Satoshi Matsumoto
Managing Executive Officer & GM of Fisheries Division
No Bio Available
Dr. Hideshi Tsusaki DVM Ph.D.
Senior MD, President of Non-Clinical & Global Business Development and Director
No Bio Available
Terumasa Hirai
Managing Executive Officer & President and Representative Director of SNBL Ina Research Center
No Bio Available
Dr. Shu-Ichi Kanazashi M.D., Ph.D.
Managing Executive Officer, CMO and General Manager of TR Business Division
No Bio Available

Contacts

Address
TOKYO-TO
Chuo-Ku
28F, St Luke's Tower, 8-1, Akashi-cho
Contacts
+81355655001.0
www.snbl.co.jp
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett